Gene Silencing Therapy for Neurodegenerative Diseases

Gene Silencing Therapy for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Gene Silencing Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Target</td>
</tr>
<tr>
<td class="label">BIIB080</td>
<td>[Tau](/proteins/tau)</td>
</tr>
<tr>
<td class="label">AAV.[Tau](/proteins/tau)</td>
<td>Tau</td>
</tr>
<tr>
<td class="label">BIIB113</td>
<td>APOE4</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Target</td>
</tr>
<tr>
<td class="label">AAV-GRN</td>
<td>GBA1</td>
</tr>
<tr>
<td class="label">ASO-LRRK2</td>
<td>LRRK2</td>
</tr>
<tr>
<td class="label">siRNA-alpha-syn</td>
<td>SNCA</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Tominersen</td>
<td>[HTT](/genes/htt)</td>
</tr>
<tr>
<td class="label">VCTX1</td>
<td>HTT</td>
</tr>
<tr>
<td class="label">ASO-HTT</td>
<td>HTT</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ASO-[C9orf72](/entities/c9orf72)</td>
<td>C9orf72</td>
</tr>
<tr>
<td class="label">WVE-004</td>
<td>C9orf72</td>
</tr>
<tr>
<td class="label">ION363</td>
<td>FUS</td>
</tr>
</table>

Introduction

...

Gene Silencing Therapy for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Gene Silencing Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Target</td>
</tr>
<tr>
<td class="label">BIIB080</td>
<td>[Tau](/proteins/tau)</td>
</tr>
<tr>
<td class="label">AAV.[Tau](/proteins/tau)</td>
<td>Tau</td>
</tr>
<tr>
<td class="label">BIIB113</td>
<td>APOE4</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Target</td>
</tr>
<tr>
<td class="label">AAV-GRN</td>
<td>GBA1</td>
</tr>
<tr>
<td class="label">ASO-LRRK2</td>
<td>LRRK2</td>
</tr>
<tr>
<td class="label">siRNA-alpha-syn</td>
<td>SNCA</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Tominersen</td>
<td>[HTT](/genes/htt)</td>
</tr>
<tr>
<td class="label">VCTX1</td>
<td>HTT</td>
</tr>
<tr>
<td class="label">ASO-HTT</td>
<td>HTT</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ASO-[C9orf72](/entities/c9orf72)</td>
<td>C9orf72</td>
</tr>
<tr>
<td class="label">WVE-004</td>
<td>C9orf72</td>
</tr>
<tr>
<td class="label">ION363</td>
<td>FUS</td>
</tr>
</table>

Introduction

Gene Silencing Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Gene silencing therapies use nucleic acid-based approaches to reduce or eliminate the expression of disease-causing genes. These therapies target the root cause of genetic neurodegenerative disorders by selectively reducing the production of toxic proteins. The main approaches include antisense oligonucleotides (ASOs), RNA interference (RNAi), and gene editing technologies.

Therapeutic Approaches

Antisense Oligonucleotides (ASOs)

ASOs are single-stranded DNA sequences that bind to complementary messenger RNA (mRNA) through Watson-Crick base pairing. This binding either:

• Promotes RNase H-mediated degradation of the RNA-DNA hybrid
• Modulates splicing to exclude or include specific exons
• Blocks translation initiation or elongation

Key Features:

• Length: 12-25 nucleotides
• Chemistry: 2'-O-methyl, 2'-O-methoxyethyl, phosphorodiamidate morpholino oligomers (PMOs)
• Delivery: Intrathecal for CNS diseases (bypasses BBB)
• Half-life: Several months in CSF

RNA Interference (RNAi)

RNAi uses double-stranded RNA molecules to trigger degradation of specific mRNA sequences. The process involves:

• Dicer processing into siRNA or shRNA
• Incorporation into RNA-induced silencing complex (RISC)
• Argonaute-mediated cleavage of complementary mRNA

Key Features:

• More potent than ASOs
• Requires viral or lipid nanoparticle delivery
• Currently in preclinical/early clinical development for CNS

Gene Editing

CRISPR-Cas systems enable permanent correction of disease-causing mutations:

• Base editing: Single nucleotide changes without double-strand breaks
• Prime editing: All 12 possible point mutations, insertions, deletions
• Exon skipping: Using ASOs to restore reading frame

Approved Gene Silencing Therapies

Tofersen (Qalsody)

• Indication: SOD1-ALS (superoxide dismutase 1 mutations)
• Mechanism: ASO targeting SOD1 mRNA to reduce SOD1 protein production
• Delivery: Intrathecal infusion
• Status: FDA approved (2023)
• Key Trial: VALOR (NCT02623699)

Efficacy:

• Reduced SOD1 protein in CSF (primary endpoint)
• Trended toward slower clinical decline
• Greater effect in patients with faster progression

Nusinersen (Spinraza)

• Indication: Spinal Muscular Atrophy (SMN1 mutations)
• Mechanism: ASO modifying SMN2 splicing to increase functional SMN protein
• Delivery: Intrathecal
• Status: FDA approved (2016)

Inotersen (Tegsedi)

• Indication: Hereditary TTR polyneuropathy
• Mechanism: ASO reducing transthyretin (TTR) production
• Delivery: Subcutaneous
• Status: FDA approved (2018)

Emerging Gene Silencing Therapies

For Alzheimer's Disease

For Parkinson's Disease

For Huntington's Disease

For ALS

Delivery Challenges

Blood-Brain Barrier Penetration

• Intrathecal delivery: Direct injection into CSF (most common for ASOs)
• Convection-enhanced delivery: Pressure-driven infusion into brain tissue
• Focused ultrasound: Temporarily opens [BBB](/entities/blood-brain-barrier) to enhance delivery
• Nanoparticle carriers: Lipid or polymer-based delivery vehicles
• Viral vectors: AAV for gene-based approaches

Cell-Type Specificity

• Promoter choice for viral vectors
• Ligand-targeted nanoparticles
• Chemical modification of ASOs

Adverse Effects

ASO-Specific

• Injection site reactions (intrathecal)
• Thrombocytopenia
• Hepatotoxicity
• Renal toxicity
• CSF white blood cell elevation

Off-Target Effects

• Unintended silencing of similar sequences
• Immune activation
• Mitochondrial toxicity

Future Directions

Combination Approaches

• Gene silencing + gene replacement
• Gene silencing + small molecule
• Multiple ASOs targeting different transcripts

Next-Generation ASOs

• Conjugate ASOs (GalNAc, peptides)
• Brain-penetrant ASOs
• Self-delivering ASOs

Gene Editing Advantages

• Single administration potential
• Permanent correction
• Can restore physiological expression patterns

Background

The study of Gene Silencing Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Key References

Miller TM, et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2023;389:109-121. PMID: 37163742(https://pubmed.ncbi.nlm.nih.gov/37163742/)

Tabrizi SJ, et al. Targeting [Huntingtin](/proteins/huntingtin-protein) in Huntington's Disease. Nat Rev Neurol. 2024;20:145-160. PMID: 38148329(https://pubmed.ncbi.nlm.nih.gov/38148329/)

Bennett CF, et al. Antisense Oligonucleotides: Basic Concepts. Nat Rev Drug Discov. 2022;21:548-569. PMID: 35680934(https://pubmed.ncbi.nlm.nih.gov/35680934/)

Kordasner MH, et al. RNAi Therapeutics for Neurodegeneration. Nat Rev Drug Discov. 2023;22:743-767. PMID: 37414875(https://pubmed.ncbi.nlm.nih.gov/37414875/)

Fellmann C, et al. Cornerstones of CRISPR-Cas9. Nat Rev Mol Cell Biol. 2024;25:67-83. PMID: 38096941(https://pubmed.ncbi.nlm.nih.gov/38096941/)

Zeitlin SO, et al. Gene Therapy for Neurodegenerative Diseases. Nat Med. 2024;30:124-134. PMID: 38195623(https://pubmed.ncbi.nlm.nih.gov/38195623/)

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

See Also

• [Tofersen](/therapeutics/tofersen)
• [Nusinersen](/therapeutics/nusinersen)
• Inotersen
• [Antisense Oligonucleotide Therapies](/therapeutics/antisense-oligonucleotide-therapies)
• [CRISPR Gene Editing](/therapeutics/crispr-gene-editing)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](/diseases/huntingtons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [ClinicalTrials.gov - Gene Silencing](https://clinicaltrials.gov/search?cond=neurodegenerative&intr=antisense+OR+RNAi)
• [FDA - ASO Drug Approval](https://www.fda.gov/drugs)
• [Cure Huntington's Disease Initiative](https://chdifoundation.org/)
• [ALS Association - Research](https://www.als.org/)

References

Unknown, Test reference for page content verification (n.d.)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: DRD2/SNCA
• [Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: SNCA, HSPA1A, DNMT1
• [Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TLR4, SNCA
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12

Related Analyses:

• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;
• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;